Alkermes plc

NASDAQ:ALKS

Biotechnology

Healthcare
$46.85 +1.77%

+$0.79 today

Market cap
$7.87B
Beta
0.33
P/E (TTM)
49.1
EPS (TTM)
$0.92
52W Low $25.17High $45.76

Volume 1.39M

Average 2.33M

ALKS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Alkermes plcNASDAQ: ALKS

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to 80.4%

Gross margin was 80.4% in Q3 FY2026, down 6.5 pp from a year earlier. On a trailing-twelve-month basis it was 82.9%, down 3.2 pp year over year. Over 3 fiscal years it widened by 6.3 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
80.4%+0.2 pp QoQ
Last fiscal yearDec 2025
86.7%+2.4 pp YoY
LTMSep 2026
82.9%-3.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.5 pp——
1 year+2.4 pp——
3 years+6.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
86.7%
Year-over-year change
+2.4pp

Gross Margin vs competitors

How ALKS compares with its peers on the latest reported figures

  • ALKS's LTM Sep 2026 gross margin of 82.9% is the 5th highest of the 7 companies compared; the peer median is 90.3%.
  • Its year-over-year change of -3.2 pp is the 5th highest of 7, against a peer median of -0.8 pp.
  • Over three fiscal years its change of +6.3 pp compares with a peer median of +2.8 pp.
ALKS Competitors Peer median
Gross Margin for ALKS and competitors
Company Period LTM level YoY 3-year change
NBIXNeurocrine Biosciences, Inc.LTM Sep 202697.8% -0.6 pp-0.3 pp
AXSMAxsome Therapeutics, Inc.LTM Jun 202693.2% +1.8 pp+3.0 pp
VNDAVanda Pharmaceuticals Inc.LTM Mar 202692.5% -1.0 pp+3.5 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202688.1% -0.5 pp+2.7 pp
ALKSAlkermes plcLTM Sep 202682.9% -3.2 pp+6.3 pp
ACADACADIA Pharmaceuticals Inc.LTM Sep 202664.9% -27.0 pp-6.3 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202664.2% -21.2 pp+3.0 pp
Peer median (excluding ALKS) 90.3%-0.8 pp+2.8 pp

Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.17B1.11B1.66B1.56B1.48B
Cost of Revenue197.32M218.07M253.04M245.33M196.46M
Gross Profit976.43M893.73M1.41B1.31B1.28B
Gross Margin83.2%80.4%84.8%84.2%86.7%
Research & Development290.92M272.7M270.81M245.33M323.96M
Selling, General & Admin549.61M590.75M689.75M645.24M714.52M
Operating Expenses878.68M899.82M996.25M891.67M1.03B
Depreciation & Amortization78.65M77.86M74.93M28.53M27.17M
EBITDA177.6M59.77M519.48M494.86M330.89M
EBITDA Margin15.1%5.4%31.2%31.8%22.4%
Operating Income97.75M(6.09M)414.12M420.64M253.96M
Operating Margin8.3%-0.5%24.9%27.0%17.2%
Interest Income2.41M7.63M30.85M42.45M45.3M
Interest Expense11.22M13.04M23.03M22.58M12.28M
Other Income / Expenses(10.02M)(25.04M)7.4M23.11M37.49M
Income Before Tax87.73M(31.13M)421.52M443.75M291.45M
Pre-Tax Margin7.5%-2.8%25.3%28.5%19.7%
Income Tax Expense11.33M2.02M(97.64M)71.61M49.79M
Net Income(48.17M)(158.27M)355.76M367.07M241.66M
Net Margin-4.1%-14.2%21.4%23.6%16.4%
EPS (Basic)(0.30)(0.97)2.142.221.47
EPS (Diluted)(0.30)(0.97)2.102.171.43
Weighted Avg Shares160.94M163.74M166.22M165.39M164.7M
Weighted Avg Shares (Diluted)160.94M163.74M169.73M169.2M168.74M

Alkermes plc

NASDAQ:ALKS

Intrinsic Alpha fair value

Locked

Current Price

$46.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.